Cytotoxic Payloads for Antibody–Drug Conjugates

Cytotoxic Payloads for Antibody–Drug Conjugates
Author :
Publisher : Royal Society of Chemistry
Total Pages : 502
Release :
ISBN-10 : 9781788018456
ISBN-13 : 1788018451
Rating : 4/5 (451 Downloads)

Book Synopsis Cytotoxic Payloads for Antibody–Drug Conjugates by : David E Thurston

Download or read book Cytotoxic Payloads for Antibody–Drug Conjugates written by David E Thurston and published by Royal Society of Chemistry. This book was released on 2019-07-11 with total page 502 pages. Available in PDF, EPUB and Kindle. Book excerpt: Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.


Cytotoxic Payloads for Antibody–Drug Conjugates Related Books

Cytotoxic Payloads for Antibody–Drug Conjugates
Language: en
Pages: 502
Authors: David E Thurston
Categories: Medical
Type: BOOK - Published: 2019-07-11 - Publisher: Royal Society of Chemistry

GET EBOOK

Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and
Antibody-Drug Conjugates
Language: en
Pages: 474
Authors: Kenneth J. Olivier, Jr.
Categories: Medical
Type: BOOK - Published: 2016-11-14 - Publisher: John Wiley & Sons

GET EBOOK

Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety a
Antibody-Drug Conjugates
Language: en
Pages: 0
Authors: Laurent Ducry
Categories: Medical
Type: BOOK - Published: 2016-08-23 - Publisher: Humana

GET EBOOK

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal anti
Chemical Linkers in Antibody-Drug Conjugates (ADCs)
Language: en
Pages: 477
Authors: Floris van Delft
Categories: Medical
Type: BOOK - Published: 2021-12-22 - Publisher: Royal Society of Chemistry

GET EBOOK

Chemical Linkers in Antibody-Drug Conjugates aims to shine a detailed light on the various key attributes of chemical linkers in ADCs, for drug-to-antibody rati
Innovations for Next-Generation Antibody-Drug Conjugates
Language: en
Pages: 358
Authors: Marc Damelin
Categories: Medical
Type: BOOK - Published: 2018-05-29 - Publisher: Springer

GET EBOOK

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of